
The AlphaLISA™ SureFire® Ultra™ Human IRF5 Aggregate assay is a sandwich immunoassay for quantitative detection of IRF5 aggregate in cellular lysates using Alpha Technology.
Feature | Specification |
---|---|
Application | Cell Signaling |
Protocol Time | 2h at RT |
The AlphaLISA™ SureFire® Ultra™ Human IRF5 Aggregate assay is a sandwich immunoassay for quantitative detection of IRF5 aggregate in cellular lysates using Alpha Technology.
Interferon regulator factor 5, IRF5, is a transcriptional regulator of type I interferon (IFN-alpha and IFN-beta)-dependent immune responses. This transcription factor plays a key role in the innate immune response against DNA and RNA viruses. IRF5 is present in the cytoplasm of uninfected cells in an inactive form. Various mediators of the pathways that follow viral infection can overexpress and phosphorylate IRF5. IRF5 is associated with various cancers and autoimmune diseases.
The AlphaLISA SureFire Ultra Human IRF5 Aggregate Detection Kit is a sandwich immunoassay for the quantitative detection of aggregate IRF5 in cellular lysates, using Alpha Technology.
Formats:
AlphaLISA SureFire Ultra kits are compatible with:
AlphaLISA SureFire Ultra kits can be used for:
Application |
Cell Signaling
|
---|---|
Automation Compatible |
Yes
|
Brand |
AlphaLISA SureFire Ultra
|
Detection Modality |
Alpha
|
Protocol Time |
2h at RT
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
IRF5
|
Target Class |
Phosphoproteins
|
Target Species |
Human
|
Technology |
Alpha
|
Therapeutic Area |
Autoimmunity
Oncology
|
Unit Size |
500 assay points
|
The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.
The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells' viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.
RPMI 8226 cells were seeded in a 96-well plate (500,000 cells/well) in complete medium and incubated for approximately 10 minutes at 37°C, 5% CO2. The cells were then treated with increasing concentrations of CpG-B ODN 2006 for 3 hours.
After treatment, the cells were spun down at 1200 rpm for 5 minutes, washed with HBSS + 0.1% BSA and lysed with 50 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Aggregate, Phospho (Ser446) and Total IRF5 levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 50,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, CpG-B ODN 2006 triggered a dose-dependent increase in the levels of Aggregate and Phospho (Ser446) IRF5 while Total IRF5 levels remained unchanged.
THP-1 cells were seeded in a 96-well plate (200,000 cells/well) in complete medium and incubated for approximately 10 minutes at 37°C, 5% CO2. The cells were treated with increasing concentrations of Calyculin A for 3 hours.
After treatment, the cells were spun down at 1200 rpm for 5 minutes, washed with HBSS + 0.1% BSA and lysed with 50 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Aggregate, Phospho (Ser446) and Total IRF5 levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 50,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, Calyculin A triggered a dose-dependent increase in the levels of Aggregate and Phospho (Ser446) IRF5 while Total IRF5 levels remained unchanged.
Are you looking for resources, click on the resource type to explore further.
The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay
Several biological processes are regulated by...
Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...
This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...
We are here to answer your questions.